QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Surawicz, T. S. Search for Related Content PubMed PubMed Citation

Descriptive epidemiology of primary brain and CNS tumors: Results from the Central Brain Tumor Registry of the United States, 1990-1994

Division of Epidemiology and Biostatistics [T.S.S., B.J.M., V.K., P.J.J., F.G.D.], School of Public Health, University of Illinois at Chicago, IL 60612; and Department of Pathology [J.M.B.], M.D. Anderson Cancer Center, University of Texas, Houston, TX 77030-4095

² Address correspondence and reprint requests to Tanya Surawicz, Division of Epidemiology and Biostatistics (M/C 922), School of Public Health, University of Illinois at Chicago, 2121 West Taylor Street, Chicago, IL 60612-7260.

Abstract

The Central Brain Tumor Registry of the United States (CBTRUS) obtained 5 years of incidence data (1990-1994)—including reports on all primary brain and CNS tumors—from 11 collaborating state cancer registries. Data were available for 20,765 tumors located in the brain, meninges, and other CNS sites, including the pituitary and pineal glands. The average annual incidence was estimated at 11.5 cases per 100,000 person-years. The higher incidence of tumors in male patients (12.1 per 100,000 person-years) than in female patients (11.0 per 100,000 person-years) was statistically significant (P<0.05); the higher incidence in whites (11.6 per 100,000 person-years) compared with blacks (7.8 per 100,000 person-years) was statistically significant (P<0.05). The most frequently reported histologies were meningiomas (24.0%) and glioblastomas (22.6%). Higher rates for glioblastomas, anaplastic astrocytomas, oligodendrogliomas, anaplastic oligodendrogliomas, ependymomas, mixed gliomas, astrocytomas not otherwise specified, medulloblastomas, lymphomas, and germ cell tumors in male than in female patients were statistically significant (P<0.05), with relative risks (RR) ranging from 1.3 to 3.4. Meningiomas were the only tumors with a significant excess in females (RR=0.5). We noted higher occurrence rates in whites than in blacks for the following histologies: diffuse astrocytomas, anaplastic astrocytomas, glioblastomas, oligodendrogliomas, ependymomas, mixed gliomas, astrocytomas NOS, medulloblastomas, nerve sheath tumors, hemangioblastomas, and germ cell tumors, with RRs ranging from 1.5 to 3.4. Racial differences in occurrence rates were not observed for predominately benign meningiomas or pituitary tumors. This study represents the largest compilation of data on primary brain and CNS tumors in the United States. Standard reporting definitions and practices must be universally adopted to improve the quality and use of cancer registry data.

This article has been cited by other articles:

				E. R. Smith, D. Zurakowski, A. Saad, R. M. Scott, and M. A. Moses Urinary Biomarkers Predict Brain Tumor Presence and Response to Therapy Clin. Cancer Res., April 15, 2008; 14(8): 2378 - 2386. [Abstract] [Full Text] [PDF]

				C.-H. Toh, M. Castillo, A.M.-C. Wong, K.-C. Wei, H.-F. Wong, S.-H. Ng, and Y.-L. Wan Primary Cerebral Lymphoma and Glioblastoma Multiforme: Differences in Diffusion Characteristics Evaluated with Diffusion Tensor Imaging AJNR Am. J. Neuroradiol., March 1, 2008; 29(3): 471 - 475. [Abstract] [Full Text] [PDF]

				M. Inglese, S. Brown, G. Johnson, M. Law, E. Knopp, and O. Gonen Whole-Brain N-Acetylaspartate Spectroscopy and Diffusion Tensor Imaging in Patients with Newly Diagnosed Gliomas: A Preliminary Study AJNR Am. J. Neuroradiol., November 1, 2006; 27(10): 2137 - 2140. [Abstract] [Full Text] [PDF]

				S. Cha, L. Yang, G. Johnson, A. Lai, M.-H. Chen, T. Tihan, M. Wendland, and W.P. Dillon Comparison of Microvascular Permeability Measurements, Ktrans, Determined with Conventional Steady-State T1-Weighted and First-Pass T2*-Weighted MR Imaging Methods in Gliomas and Meningiomas. AJNR Am. J. Neuroradiol., February 1, 2006; 27(2): 409 - 417. [Abstract] [Full Text] [PDF]

				S. Hoffman, J. M. Propp, and B. J. McCarthy Temporal trends in incidence of primary brain tumors in the United States, 1985-1999 Neuro-oncol, January 1, 2006; 8(1): 27 - 37. [Abstract] [Full Text] [PDF]

				B. A. Cohen, E. A. Knopp, H. Rusinek, J. S. Babb, D. Zagzag, and O. Gonen Assessing Global Invasion of Newly Diagnosed Glial Tumors with Whole-Brain Proton MR Spectroscopy AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2170 - 2177. [Abstract] [Full Text] [PDF]

				B. A. Cohen, E. A. Knopp, H. Rusinek, S. Liu, and O. Gonen Brain Compression without Global Neuronal Loss in Meningiomas: Whole-Brain Proton MR Spectroscopy Report of 2 Cases AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2178 - 2182. [Abstract] [Full Text] [PDF]

				Z. Fang, M. Kulldorff, and D. I. Gregorio Brain cancer mortality in the United States, 1986 to 1995: A geographic analysis Neuro-oncol, July 1, 2004; 6(3): 179 - 187. [Abstract] [PDF]

				S. L. Chua, M. A. Rosenthal, S. S. Wong, D. M. Ashley, A.-m. Woods, A. Dowling, and L. M. Cher Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme Neuro-oncol, January 1, 2004; 6(1): 38 - 43. [Abstract] [PDF]

				I-M. Siu, A. Lal, J. R. Blankenship, N. Aldosari, and G. J. Riggins c-Myc Promoter Activation in Medulloblastoma Cancer Res., August 15, 2003; 63(16): 4773 - 4776. [Abstract] [Full Text] [PDF]

				M. Wrensch, Y. Minn, T. Chew, M. Bondy, and M. S. Berger Epidemiology of primary brain tumors: Current concepts and review of the literature Neuro-oncol, October 1, 2002; 4(4): 278 - 299. [Abstract] [PDF]

				U. Buhring, U. Herrlinger, T. Krings, R. Thiex, M. Weller, and W. Kuker MRI features of primary central nervous system lymphomas at presentation Neurology, August 14, 2001; 57(3): 393 - 396. [Abstract] [Full Text] [PDF]

				P. J. Jukich, B. J. McCarthy, T. S. Surawicz, S. Freels, and F. G. Davis Trends in incidence of primary brain tumors in the United States, 1985-1994 Neuro-oncol, July 1, 2001; 3(3): 141 - 151. [Abstract] [PDF]

				F. G. Davis, V. Kupelian, S. Freels, B. McCarthy, and T. Surawicz Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups Neuro-oncol, July 1, 2001; 3(3): 152 - 158. [Abstract] [PDF]

				M. A. Rosenthal, B. Kavar, J. S. Hill, D. J. Morgan, R. L. Nation, S. S. Stylli, R. L. Basser, S. Uren, H. Geldard, M. D. Green, et al. Phase I and Pharmacokinetic Study of Photodynamic Therapy for High-Grade Gliomas Using a Novel Boronated Porphyrin J. Clin. Oncol., January 15, 2001; 19(2): 519 - 524. [Abstract] [Full Text] [PDF]

				A Das, C A T Chapman, and W M Yap Histological subtypes of symptomatic central nervous system tumours in Singapore J. Neurol. Neurosurg. Psychiatry, March 1, 2000; 68(3): 372 - 374. [Abstract] [Full Text] [PDF]